Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

Trial Identifier: D7000C00004
Sponsor: AstraZeneca
NCTID:: NCT05872958
Start Date: May 2023
Primary Completion Date: August 2024
Study Completion Date: August 2024
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, AL Anniston, AL, US, 36207
US, AL Cullman, AL, US, 35055
US, AZ Scottsdale, AZ, US, 85260
US, CA San Diego, CA, US, 92103
US, Florida Orlando, Florida, US, 32819
US, KS Overland Park, KS, US, 66212